1. Mesoporous molecularly imprinted polymer nanoparticles as a sustained release system of Azithromycin
Simin Sheybani,* Tolou Hosseinifar, Majid Abdouss* and Saeedeh Mazinani. RSC Adv.,2015, 5, 98880–98891
In this paper, azithromycin (AZM) was used to study its release profile in MIP nanoparticles. Azithromycin, (9-deoxo-9a-aza-9a-methyl-9a-homoerythromycin), is the first semi-synthetic macrolide antibiotic belonging to the azalide group that is derived from erythromycin. In structure of azithromycin compared with erythromycin, an extra positive charge created by the insertion of amethyl-substituted nitrogen in place of carbonyl group at the 9a position of the aglycone ring. This significantly results in increasing the serum half-life, tissue penetration and antibacterial activity against gram-negative bacteria and decreasing antibacterial activity against some gram-positive bacteria. Although, AZM has been widely used for the treatment of respiratory tract infections, skin and soft tissue infections, urinary tract infections and sexually transmitted diseases, however it exhibited a low bioavailability of approximately 37% following an oral administration.
2. Predicting the optimum compositions of a parenteral nanoemulsion system loaded with azithromycin antibiotic utilizing the artiﬁcial neural network model
Ghaidaa S. Daood, Hamidon Basri,* Johnson Stanslas. RSC Adv.,2015, 5, 82654–82665
Azithromycin (9-deoxo-9a-aza-9a-methyl-9a-homoerthromycin) is a semi-synthetic antibiotic “derived from the naturally occurring antibiotic erythromycin”; it represents the first of a subclass of macrolides classified as azalides. Azithromycin was first produced in the 1980s by the insertion of a methyl-substituted nitrogen on the lactone ring of erythromycin at position 9a, creating a 15-membered macrolide.